摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(4-氰基苯基)甲烷磺酰氯 | 56105-99-8

中文名称
(4-氰基苯基)甲烷磺酰氯
中文别名
(4-氰基苯基)甲磺酰氯
英文名称
(4-cyano-phenyl)-methanesulfonyl chloride
英文别名
(4-Cyanophenyl)methanesulfonyl chloride
(4-氰基苯基)甲烷磺酰氯化学式
CAS
56105-99-8
化学式
C8H6ClNO2S
mdl
MFCD07690517
分子量
215.66
InChiKey
UKKQISHRHXSEGI-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    99.5 °C
  • 溶解度:
    可溶于DMSO(轻微),四氢呋喃(非常轻微,加热)

计算性质

  • 辛醇/水分配系数(LogP):
    1.6
  • 重原子数:
    13
  • 可旋转键数:
    2
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.125
  • 拓扑面积:
    66.3
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 海关编码:
    2926909090

SDS

SDS:af45b369bd01464201bf3fd54e887a33
查看
Material Safety Data Sheet

Section 1. Identification of the substance
Product Name: (4-Cyanophenyl)methanesulfonyl chloride
Synonyms:

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

Section 3. Composition/information on ingredients.
Ingredient name: (4-Cyanophenyl)methanesulfonyl chloride
CAS number: 56105-99-8

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C8H6ClNO2S
Molecular weight: 215.7

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride, sulfur oxides.

Section 11. Toxicological information
No data.

Section 12. Ecological information
No data.

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

Section 14. Transportation information
Non-harzardous for air and ground transportation.

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.


SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

(4-氰基苯基)甲烷磺酰氯可用作医药合成中间体,主要用于实验室研发过程和化工医药合成过程中。作为一类重要的有机和药物合成中间体及原料,它能够用于合成带有磺酰基的药物分子。与胺反应后可得到磺酰胺,而磺酰胺是许多药物活性结构单元的重要组成部分。

制备方法如下:将硫脲(0.387g,5mmol)和对硝基苄氯(0.633g,5mmol)加入到5mL乙醇中,回流反应30分钟后,减压除去溶剂得白色固体S-苄基异硫脲盐。将此白色固体直接缓慢加入到2mL 6MH2SO4(12mmol)中,然后加入30mL乙醚,在冰水浴条件下缓慢滴加30mL新出厂的5%NaClO溶液,确保反应体系温度控制在10-20℃之间。滴加完毕后,继续反应15分钟。反应结束后进行分液,所得有机相用无水Na2SO4干燥,蒸除溶剂得到产物(4-氰基苯基)甲烷磺酰氯,为无色晶体,熔点92-94℃,产率93%,重量0.886g。

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (4-氰基苯基)甲烷磺酰氯ammonium hydroxide碳酸氢铵 作用下, 以 四氢呋喃 为溶剂, 反应 1.0h, 以0.8 g的产率得到1-(4-氰基苯基)甲基磺酰胺
    参考文献:
    名称:
    P2Y12拮抗剂乙基6-(4-((苯甲磺酰基)氨基甲酰基)哌啶-1-基)-5-氰基-2-甲基烟酸酯(AZD1283)的优化导致发现具有改善的类药物特性的口服抗血小板药。
    摘要:
    P2Y12拮抗剂广泛用作预防和治疗动脉血栓形成的抗血小板药。基于已知的P2Y12拮抗剂AZD1283的支架,设计和合成了一系列新型的双环吡啶衍生物。吡啶环上的酯取代基与邻甲基的环化作用导致AZD1283的内酯类似物在随后的结构-药代动力学关系研究中显示出显着增强的代谢稳定性。通过向哌啶基部分添加4-甲基取代基进一步增强了代谢稳定性。在大鼠氯化铁模型中,化合物58l在体外显示出对血小板聚集的有效抑制以及抗血栓形成的功效。而且,58l显示出的安全性优于在大鼠尾巴出血模型中观察到的氯吡格雷的安全性。这些结果支持进一步评价化合物58l作为有前途的候选药物。
    DOI:
    10.1021/acs.jmedchem.8b01971
  • 作为产物:
    描述:
    sodium (4-cyanophenyl)methanesulfonate氯化亚砜 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 以66.9 g的产率得到(4-氰基苯基)甲烷磺酰氯
    参考文献:
    名称:
    通过 α-取代的甲磺酰苯胺的环二烷基化获得广泛的 Sultam
    摘要:
    在存在下,通过 α-取代的甲磺酰苯胺与 α,ω-二卤代烷烃的环二烷基化,合成了各种带有 α-乙氧基羰基-α-甲基取代基或 α-芳基的五元和六元磺胺(17 个例子) K2CO3 或在相转移催化 (PTC) 条件下。用 N,N-二甲基甲酰胺 (DMF) 中的 K2CO3 或二甲亚砜 (DMSO) 中的 NaH 处理后,N-(2,3-二溴丙基)-α-甲苯磺酰苯胺提供不同的 1,3-二芳基-2-硫杂-3-氮杂双环[3.1.0] 己烷 2,2-二氧化物的产率从良好到极好(51-88%,16 个实例)。通过在乙腈中用硝酸铈 (IV) 铵处理相应的双环 sultam,可以轻松地从 sultam 氮原子中去除 4-甲氧基苯基 (PMP) 基团(产率 71-84%,6 个实例)。
    DOI:
    10.1002/ejoc.201200670
点击查看最新优质反应信息

文献信息

  • Clean and Economic Synthesis of Alkanesulfonyl Chlorides from S-Alkyl Isothiourea Salts via Bleach Oxidative Chlorosulfonation
    作者:Jiaxi Xu、Zhanhui Yang、Bingnan Zhou
    DOI:10.1055/s-0033-1338567
    日期:——
    Abstract A simple procedure for clean and economic synthesis of alkanesulfonyl chlorides via bleach-mediated oxidative chlorosulfonation of S-alkyl isothiourea salts is disclosed. This procedure is environment- and worker-friendly with the advantages of readily accessible materials and reagents, simple and safe operations, easy purification without chromatography, and affords high yields of up to 99%
    摘要 公开了通过漂白介导的S-烷基异硫脲盐的氧化氯磺化来清洁和经济地合成烷烃磺酰氯的简单方法。该方法对环境和工人均有利,具有易于获得的材料和试剂,简单安全的操作,无需色谱法即可轻松纯化的优点,并提供高达99%的高收率。 公开了通过漂白介导的S-烷基异硫脲盐的氧化氯磺化来清洁和经济地合成烷烃磺酰氯的简单方法。该方法对环境和工人均有利,具有易于获得的材料和试剂,简单安全的操作,无需色谱法即可轻松纯化的优点,并提供高达99%的高收率。
  • Discovery and Characterization of XY101, a Potent, Selective, and Orally Bioavailable RORγ Inverse Agonist for Treatment of Castration-Resistant Prostate Cancer
    作者:Yan Zhang、Xishan Wu、Xiaoqian Xue、Chenchang Li、Junjian Wang、Rui Wang、Cheng Zhang、Chao Wang、Yudan Shi、Lingjiao Zou、Qiu Li、Zenghong Huang、Xiaojuan Hao、Kerry Loomes、Donghai Wu、Hong-Wu Chen、Jinxin Xu、Yong Xu
    DOI:10.1021/acs.jmedchem.9b00327
    日期:2019.5.9
    complex with the RORγ ligand binding domain provided a solid structural basis for its antagonistic mechanism. 27 potently inhibited cell growth, colony formation, and the expression of AR, AR-V7, and PSA. 27 also exhibited good metabolic stability and a pharmacokinetic profile with oral bioavailability of 59% and a half-life of 7.3 h. Notably, 27 demonstrated promising therapeutic effects with significant
    我们报告了核受体RORγ反向激动剂作为前列腺癌治疗药物的设计,优化和生物学评估。最有效的化合物27(指定为XY101)在基于细胞的报告基因分析中表现出细胞活性,IC50值为30 nM,对其他核受体亚型具有良好的选择性。27与RORγ配体结合域复合的共晶体结构为其拮抗机制提供了坚实的结构基础。27有效抑制细胞生长,集落形成以及AR,AR-V7和PSA的表达。27还表现出良好的代谢稳定性和药代动力学特征,口服生物利用度为59%,半衰期为7.3小时。尤其,图27显示了在小鼠的前列腺癌异种移植模型中具有显着的肿瘤生长抑制作用的有希望的治疗作用。有效的,选择性的,代谢稳定的和口服可用的RORγ反向激动剂代表了一类新型化合物,可作为对抗前列腺癌的潜在疗法。
  • [EN] PHENOXY-PYRIDYL-PYRIMIDINE COMPOUNDS AND METHODS OF USE<br/>[FR] COMPOSÉS PHÉNOXY-PYRIDYL-PYRIMIDINE ET MÉTHODES D'UTILISATION ASSOCIÉES
    申请人:GENENTECH INC
    公开号:WO2020056089A1
    公开(公告)日:2020-03-19
    Described herein are phenoxy-pyridyl -pyrimidine compounds with inositol requiring enzyme 1 (IRE1) modulation activity or function having the Formula I structure or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, and with the substituents and structural features described herein. Also described are pharmaceutical compositions and medicaments that include the Formula I compounds, as well as methods of using such IRE1 modulators, alone and in combination with other therapeutic agents, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    本文描述了具有肌醇需要酶1(IRE1)调节活性或功能的苯氧基吡啶基嘧啶化合物,其具有Formula I结构或立体异构体、互变异构体或其药用可接受的盐,并具有所述的取代基和结构特征。还描述了包括Formula I化合物的药物组合物和药物,以及使用这种IRE1调节剂的方法,单独或与其他治疗剂联合使用,用于治疗通过雌激素受体介导或依赖的疾病或症状。
  • Straightforward Route to γ-Sultams via Novel Tandem SN/Michael Addition
    作者:Olga Bakulina、Anastasiia Klochkova、Andrey Bubyrev、Dmitry Dar’in、Mikhail Krasavin、Viktor Sokolov
    DOI:10.1055/a-1343-9451
    日期:2021.5
    A novel tandem approach to trisubstituted γ-sultams has been developed involving N-alkylation of methanesulfonanilides with EWG-substituted allyl bromides followed by intramolecular Michael addition. A series of various isothiazolidine 1,1-dioxides have been prepared under mild transition-metal-free conditions in high yields and trans-diastereoselectivity (confirmed by X-ray crystallography). The dependence
    已经开发出一种新颖的串联三取代的γ-sultams方法,包括用EWG取代的烯丙基溴对甲磺酰苯胺进行N-烷基化,然后进行分子内迈克尔加成。已在温和的无过渡金属条件下以高收率和反式非对映选择性(由X射线晶体学证实)制备了一系列各种异噻唑烷1,1-二氧化物。已经研究了反应性对基材的电子性能的依赖性。
  • tert-Butyl Hypochlorite Mediated Oxidative Chlorination of S-Alkylisothiourea Salts: Synthesis of Sulfonyl Chlorides
    作者:Kui Qiu、Rennan Wang
    DOI:10.1055/s-0034-1381024
    日期:——
    Cbz-protecting group was not affected. Under neutral conditions, a variety of S-alkylisothiourea salts were smoothly converted into the corresponding sulfonyl chlorides through tert-butyl chlorite mediated oxidative chlorination in good to excellent yields after simple purification. In addition to the environmental and procedural advantages of this method, the neutral conditions potentially make it applicable
    摘要 在中性条件下,通过简单的纯化后,通过亚氯酸叔丁酯介导的氧化氯化,将各种S-烷基异硫脲盐平稳地转化为相应的磺酰氯。除了此方法的环境和程序优势外,中性条件还可能使其适用于带有酸敏感官能团的底物。例如,在当前的中性条件下,可以中等至良好的产率合成Cbz保护的2-氨基乙烷磺酰氯,并且酸敏感的Cbz保护基不受影响。 在中性条件下,通过简单的纯化后,通过亚氯酸叔丁酯介导的氧化氯化,将各种S-烷基异硫脲盐平稳地转化为相应的磺酰氯。除了此方法的环境和程序优势外,中性条件还可能使其适用于带有酸敏感官能团的底物。例如,在当前的中性条件下,可以中等至良好的产率合成Cbz保护的2-氨基乙烷磺酰氯,并且酸敏感的Cbz保护基不受影响。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐